Biliary Tract Cancer New Protocol: Tucatinib and Trastuzumab in her2-Positive Biliary Tract Cancer Ulas D. Bayraktar, MD 2023-06-24
Renal Cell Carcinoma New Protocol: Belzutifan and Cabozantinib for Advanced RCC Ulas D. Bayraktar, MD 2023-06-24
Prostate Cancer New Indication: Talazoparib and Enzalutamide in Metastatic CRPC Ulas D. Bayraktar, MD 2023-06-24
Breast Cancer New Indication: Adjuvant Ribociclib and Endocrine Therapy in Breast Cancer Ulas D. Bayraktar, MD 2023-06-24
Diffuse Large B Cell Lymphoma New Protocol: Rituximab, Lenalidomide, and Ibrutinib in DLBCL Ulas D. Bayraktar, MD 2023-06-14
Skin Cancer (Other than Melanoma) New Indication: Neoadjuvant Cemiplimab for Cutaneous Squamous Cell Cancer Ulas D. Bayraktar, MD 2023-06-14
Bladder Cancer New Indication: Durvalumab with CISplatin and Gemcitabine in Biliary Tract Cancers Ulas D. Bayraktar, MD 2023-06-14
Non-Hodgkin Lymphoma Primary Mediastinal Large B-cell Lymphoma New Reference: Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma Ulas D. Bayraktar, MD 2023-06-07
